Back to Trials
NCT06876649PHASE4Recruiting

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Eli Lilly and Company

Start Date

5/20/2025

Completion Date

12/1/2032

Summary

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib. Exclusion Criteria: Exclusion criteria are defined in each ISA.

Interventions

DRUG

Pirtobrutinib

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma

Locations

Cancer Specialists, LLC

Jacksonville, Florida 32256

United States

Sylvester Comprehensive Cancer Center

Miami, Florida 33136-1002

United States

Florida Cancer Specialists

Sarasota, Florida 34232-6422

United States

The Emory Clinic

Atlanta, Georgia 30322-1013

United States

Northwestern University

Chicago, Illinois 60611-3013

United States

Dana-Farber Cancer Institute

Boston, Massachusetts 02215

United States

Mayo Clinic- Minnesota

Rochester, Minnesota 55905

United States

University Of Nebraska Medical Center

Omaha, Nebraska 69198

United States

Cayuga Cancer Center

Ithaca, New York 14850

United States

Northwell Health

Lake Success, New York 11042-1118

United States

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

New York, New York 10065-6007

United States

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

New York, New York 10065-6007

United States

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

New York, New York 10065-6007

United States

Duke University Medical Center

Durham, North Carolina 27710-4000

United States

Ohio State University Comprehensive Cancer Center

Columbus, Ohio 43210-1063

United States

University of Pennsylvania Hospital

Philadelphia, Pennsylvania 19104

United States

Tennessee Oncology

Nashville, Tennessee 37203-2659

United States

University of Texas MD Anderson Cancer Center

Houston, Texas 77030

United States

Swedish Cancer Institute

Seattle, Washington 98104-3588

United States

Medical College of Wisconsin

Milwaukee, Wisconsin 53226-3548

United States

Flinders Medical Centre

Adelaide, 5042

Australia

Peter MacCallum Cancer Centre

Melbourne, 3000

Australia

Linear Clinical Research

Victoria, 3000

Australia

CHU de Nantes - Hotel Dieu

Nantes, 44093

France

IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi

Bologna, 40138

Italy

Ospedale San Raffaele

Milan, 20132

Italy

Nagoya Medical Center

Aichi-Ken, 4600001

Japan

National Cancer Center Hospital

Cho-ku, 104-0045

Japan

National Hospital Organization Kyushu Cancer Center

Fukuoka, 811-1395

Japan

Tokai University Hospital- Isehara Campus

Isehara, 259-1193

Japan

Tohoku University Hospital

Miyagi-Ken, 9808574

Japan

Hokkaido University Hospital

Sapporo, 060-8648

Japan

Pratia MCM Krakow

Krakow, 30727

Poland

Instytut Hermatologii I Transfuzjologii

Warsaw, 02776

Poland

Seoul National University Hospital

Seoul, 03080

South Korea

St James's University Hospital

Leeds, LS9 7TF

United Kingdom

Churchill Hospital

Oxford, OX3 7LE

United Kingdom

Derriford Hospital

Plymouth, PL6 8DH

United Kingdom